Why an ICEYE or IQM Could Almost Never Be Born Inside a European Industrial Giant

• Europe’s industrial giants are not short of science. They are short of mechanisms that convert science into new companies and new markets.
• Public-company governance rewards predictability, capital discipline and dividend resilience more than long-duration venture bets.
• The same deep technology that becomes a startup in one context often becomes a feature, a patent or a product upgrade in another.
• If Europe wants more ICEYEs and IQMs, it must build a bridge from research to venture creation rather than assuming corporate R&D alone will do the job.

Deep technology research thrives inside large corporations. Yet the companies that turn such breakthroughs into new markets are almost always startups. Why?

Europe likes to tell itself a comforting story about innovation. It is a continent of first-rate engineers, serious industrial capabilities and world-class scientific institutions. Its large companies fund laboratories, sponsor doctoral work, employ excellent applied researchers and file no shortage of patents. Finland alone offers a particularly neat version of the tale: a small country with deep technical competence, strong universities, sophisticated industrial firms and a policy apparatus explicitly designed to encourage research and development.

Yet a nagging question refuses to go away. If the science is good, the engineers are good and the industrial base is strong, why do so many of the most interesting new deep-tech growth stories emerge not from inside Europe’s industrial incumbents but outside them?

Why did a company such as ICEYE, which helped commercialise synthetic-aperture radar satellites, emerge as a startup rather than as an internal venture inside a large aerospace, defence or industrial player? Why did IQM take shape as a standalone quantum-computing company rather than as a business line within a European electronics or engineering conglomerate? Why do companies such as Oura or Kempower look more plausible as young firms built around a market thesis than as internal projects inside an established corporation, even though the underlying science, sensors, materials and systems integration could easily have sat inside a corporate R&D function?

The easy answer is to say that big companies have become timid. The more useful answer is that they have become rational.

That distinction matters. The problem is not usually a lack of imagination inside large companies. Nor is it a shortage of technical ambition. It is that the structures optimised for running a listed industrial company are not the same as the structures required to build a new market from uncertain science. The public company and the venture are built to do different things. One is designed to compound cash flows, protect returns on capital and manage downside risk. The other is designed to absorb uncertainty, tolerate failure and search for a market that may not yet exist.

Much of Europe’s innovation debate still assumes that these are simply two stages of the same pipeline. Fund more research, strengthen the ecosystem, create better collaboration and the growth companies will somehow emerge. But that assumption is too tidy. Between research and scale lies an organisational chasm. On one side stands the industrial corporation with its planning cycles, capital-allocation rules, analyst expectations and dividend norms. On the other stands the venture with its asymmetrical logic, where nine failures can be justified by one outsized success. What is missing in much of Europe is not science but a repeatable mechanism for crossing that chasm.

That is why so much promising deep research ends up as a somewhat better existing product rather than a new company defining a new category. It is also why Europe can produce strong technology and still miss much of the market upside.

The paradox of deep research

Begin with the apparent contradiction. Large industrial companies spend serious money on research and development. They have laboratories, testing facilities, customer access, domain expertise, manufacturing know-how and regulatory understanding. In sectors such as energy, industrial automation, mobility, telecommunications, healthcare technology and advanced materials, Europe’s big firms are not laggards in technical sophistication. On the contrary, many are global leaders.

And yet the companies that feel most like the future are often young.

This is not because startups do more fundamental science than large firms. Often they do not. Nor is it because corporate research is necessarily less original. Large corporations are perfectly capable of generating breakthrough insights, platform technologies and commercially meaningful intellectual property. Indeed, much of what later looks like startup innovation rests on scientific foundations that could just as easily have appeared in a corporate lab, a university research programme or a joint ecosystem project.

The paradox is therefore not about the production of knowledge. It is about the form that knowledge takes when it is commercialised.

Inside a large industrial company, a breakthrough in sensing, materials, control systems, AI, energy efficiency or digital architecture is likely to be evaluated in relation to an existing business. Can it improve an installed base? Can it raise margins in a current product family? Can it strengthen the value proposition to existing customers? Can it protect market share? Can it help the company comply with changing regulation? In this setting, the path of least resistance is clear. The science is absorbed into the corporate roadmap. It becomes a better feature set, a more competitive offering, a higher-margin service layer, a more efficient process or perhaps a defensible patent portfolio.

All of those things matter. None should be sneered at. Incremental innovation is not trivial. Most of industry’s actual competitive advantage comes from exactly such work. But it is not the same thing as creating a new market.

Young companies built around deep technology are different because they are not asking how a technology fits into an existing portfolio. They are asking what business can be built if the technology is taken as the starting point. That difference in question leads to a difference in outcome. The corporate asks how to improve the business it already has. The startup asks what new business might now be possible.

This is why the same underlying science can yield very different commercial destinies. In one setting it becomes an improved product sold to existing customers. In the other it becomes the nucleus of a new category.

The governance reality of a public company

To understand why, one must move away from romantic stories about innovation and look at governance.

The chief executive of a listed industrial company is not in the venture business, whatever speeches about transformation may suggest. He or she is in the business of producing resilient results from a large organisation under conditions of scrutiny. That means meeting earnings expectations, protecting the balance sheet, allocating capital credibly, managing investor relations, preserving strategic flexibility and maintaining confidence among employees, customers and shareholders.

The chief financial officer is even less in the venture business. The CFO’s task is to protect the company’s financial architecture: liquidity, leverage, cash conversion, returns on invested capital, cost of funding and the credibility of the numbers. None of this is pathological. It is the proper work of corporate stewardship. But it has consequences.

In practice, this creates an internal logic that privileges predictability over optionality. Executives are rewarded for visible performance, disciplined capital allocation and downside protection. They are punished for unexpected earnings weakness, balance-sheet deterioration and investments that cannot be explained in conventional financial language.

Consider the typical list of what matters in a listed industrial firm. Revenue growth matters, certainly, but so do margin quality, free cash flow, return on capital employed, working-capital discipline and payout sustainability. Strategy is not judged only by the size of the opportunity but by its effect on near- and medium-term financial coherence. A management team that can point to a stable three-year earnings trajectory, sound capital discipline and a credible dividend policy will often enjoy more market confidence than one that promises large but distant upside at the price of present uncertainty.

Once this is understood, much of the supposed timidity of industrial incumbents looks less like a failure of courage than a response to institutional design. The public company is not organised to behave like a venture fund because its stakeholders do not evaluate it as one.

Analysts, guidance and the tyranny of the visible

No account of this system is complete without the role of sell-side analysts.

In innovation discussions, analysts are often treated as background noise: people who ask questions on earnings calls and publish price targets that management privately resents. In reality, they are an important part of the behavioural machinery. A large listed company is not judged only by what it does, but by how legible what it does appears inside market models.

Those models are not built around technological possibility. They are built around forecasts. Analysts tend to care about revenue trajectories, segment margins, cash flow, capital expenditure, backlog, pricing, cost actions and the timing of inflections. They are trying to estimate what the business will earn over the next few years and what multiple the market should put on those earnings. Their work is inherently reductionist. It has to be.

What tends not to fit neatly into such models? Early-stage venture bets, long-duration research programmes, ecosystem initiatives, pilot projects and technologies whose commercial timing is uncertain. Unless these affect earnings within a reasonably foreseeable period, they rarely receive much weight. They may be mentioned in qualitative sections, but they do not usually drive base-case valuation.

That fact matters because executives understand it perfectly well. Markets reward companies that “meet or beat” expectations. They are often less generous to companies that promise a great deal and deliver later than hoped. Thus a subtle but powerful bias emerges. Management teams learn that credibility comes from controllable numbers, not from long-shot visions. Better to guide conservatively and outperform than to ask investors to underwrite a speculative journey. Better to explain visible backlog and margin discipline than to defend a portfolio of uncertain ventures.

The result is structural, not personal. If a new deep-tech initiative will not move earnings for two or three years, many analysts will not model it with conviction. If it depresses margins or increases capital expenditure in the meantime, they may treat it as a headwind. If it sits outside the current segment structure, it may appear not as a growth engine but as a source of opacity. From management’s perspective, then, the market’s message is clear: do not ask to be valued on distant optionality when you are held accountable for near-term delivery.

This does not mean analysts are foolish. They are doing the job the market asks of them. But the cumulative effect is to steer listed companies toward innovations that are forecastable, explainable and proximate to current earnings. That is precisely the habitat of incremental innovation.

The CFO problem

If analysts supply the external pressure, the CFO often personifies the internal discipline.

Inside large corporations, serious investments must pass through financial gates. The language may vary, but the criteria are familiar: payback period, internal rate of return, sensitivity analysis, downside scenarios, effects on margins, impact on cash flow, implications for the balance sheet and fit with capital-allocation priorities. It is a regime designed to separate promising investments from expensive fantasies.

Now place a deep-tech venture inside that regime.

Many such ventures require years of technical de-risking, product development, regulatory work, customer education, ecosystem building and market creation before they become profitable. They may incur significant losses early on. They may need specialised talent, new infrastructure and repeated iterations. Their cash flows are not only negative at first; they are highly uncertain. Their market may not yet be fully formed. Their customer base may need to be invented as much as won.

Viewed through a conventional corporate investment model, such projects can look dreadful. Long payback periods. Fragile assumptions. hard-to-estimate terminal economics. Material execution risk. Uncertain strategic fit. Weak short-term contribution. Potential pressure on group returns.

It is not surprising, then, that many of these ideas are gently redirected. Rather than funding a standalone venture that may not show meaningful returns for seven to ten years, the company allocates capital to projects with clearer economics: expanding capacity in proven product lines, digitising service offerings for current customers, lowering production costs, upgrading installed bases or making tuck-in acquisitions with more immediate synergies. This is not because finance departments hate innovation. It is because they are trained to ask whether a company is being paid enough for the risk it is taking.

A startup faces the same economic reality but interprets it through a different lens. Venture investors do not expect each company to clear a short payback hurdle. They expect most of them to disappoint and a minority to generate extraordinary outcomes. The mathematics of the portfolio absorbs what would look intolerable inside a corporate budgeting process. That is why deep tech can look unattractive in one system and compelling in another.

The portfolio-fit constraint

Another important filter is strategic fit.

When a new technology emerges inside a corporation, one of the first questions asked is deceptively simple: does this fit our business? It is a sensible question. Corporate resources should not be scattered at random. But as a selection mechanism it is profoundly conservative.

If the answer is yes, the technology may be incorporated into a current roadmap. If the answer is no, the organisation becomes uneasy. What is the owner? Which business unit will house it? How will revenues be reported? Will it cannibalise something else? Does it require capabilities the firm does not have? Does it make the corporate story harder to explain? Is it adjacent enough to justify management attention?

These are all rational questions. Yet together they create a bias towards ideas that resemble what the firm already knows how to do. A technology that can improve the competitiveness of a current offering is welcome. One that requires a new customer base, a new operating model or a new category of sales motion is more problematic. So it is piloted, studied, postponed, licensed, partnered or quietly repurposed into an enhancement of the existing portfolio.

Rarely does the corporation conclude: this does not fit our current business, therefore we should build a new company around it.

That is the missing move. It is also the one that matters most if the ambition is to create new markets rather than strengthen current positions.

Why startups can pursue the same science differently

Startups are not magically more visionary. They are merely governed differently.

A startup built around deep technology is not judged on dividend sustainability, segment margins next year or whether analysts can model its contribution to group EBIT. It is judged on a very different bundle of criteria: whether the market opportunity is large enough, whether the technology can create a genuine advantage, whether the founders can execute, whether customers will eventually care and whether the upside is asymmetric enough to justify the risk.

That is why startups can pursue the same science in a different manner. They are not trying to fit a technology into a portfolio. They are trying to build a company around the consequences of the technology. That opens strategic possibilities that a large industrial firm often closes by default.

The venture model makes this feasible. Investors expect a skewed distribution of outcomes. Most investments will not become category leaders. A few may become very valuable indeed. The entire system is built around that asymmetry. Founders are granted equity. Losses are tolerated. Time horizons are longer. Narrative matters because markets often have to be constructed, not merely served. Failure is not pleasant, but it is legible within the logic of the asset class.

Corporate governance cannot easily operate on that basis. Nor should it. The listed industrial company is not supposed to tell shareholders that nine of its ten new ventures may fail but the tenth could justify the effort. That would not be stewardship; it would be dereliction of its role as currently constituted. The implication, however, is clear. If the economic logic required for new-market creation is fundamentally portfolio-based and tolerant of asymmetric risk, then expecting large public companies to produce such outcomes routinely from inside the core is a category error.

Where corporate R&D actually goes

At this point it is worth correcting a common misconception. To say that corporate R&D rarely creates new markets is not to say that it is wasted.

Far from it. Large-company research generates enormous value. It improves products, reduces failure rates, enhances efficiency, deepens customer relationships, supports premium pricing, strengthens service models, creates intellectual property and maintains technological relevance. In mature industrial sectors, this is not peripheral activity. It is often the difference between leadership and decline.

Moreover, many corporate innovations are genuinely substantial. A more efficient propulsion system, a smarter automation architecture, a better diagnostic layer, a low-emissions industrial process, a safer power-management platform or a more capable sensor suite can all create serious commercial value. They may even reshape competitive dynamics within a sector. But they do so within an existing market frame.

That is the key distinction. Corporate R&D often excels at product superiority. It is less consistently structured for market genesis.

The science therefore does not disappear. It is translated into a form the corporation can metabolise. It becomes the next generation of the business rather than the first generation of a new one.

This helps explain the recurring European frustration. Policymakers see large volumes of research, patents and collaborative projects, yet the number of breakout new companies remains modest. The missing link is not invention but institutional conversion.

Finland’s problem is not science

Finland provides an instructive case because it is unusually strong in the inputs that innovation policy likes to celebrate. Its technical universities are serious. Its engineering culture is rigorous. Its companies know how to build things that work. Its public institutions support R&D. Its industrial ecosystems are dense enough that collaboration is plausible rather than rhetorical. And in several domains the country has produced startups that are genuinely world class.

The difficulty is not the generation of deep research. It is the systematic turning of deep research into new firms with the mandate and financing to pursue category creation. In many ecosystems, research collaboration naturally orients itself around the needs of the lead company. That makes sense. Industrial relevance matters. So do customer access, domain context and the practical discipline that real-world engineering imposes.

But such ecosystems often optimise for technology development rather than venture creation. They produce useful results, but the default path for those results is toward the roadmap of the incumbent. Without a mechanism that explicitly asks whether some of that science ought to become a standalone company, the outcome is predictable. The ecosystem strengthens the core business. It does not necessarily spawn a new one.

This is why Europe can have strong research intensity and still feel short of growth companies. The pipeline is built to enrich incumbents, not systematically to create challengers.

The macroeconomic cost

The consequences are not merely organisational; they are continental.

Europe has no fundamental shortage of scientists, engineers or industrial domains in which deep technology matters. What it struggles with is the translation of these assets into outsized new companies. When that translation fails, several things happen.

First, much of the upside from breakthrough technologies accrues elsewhere. Europe may generate part of the underlying science, but the market-defining company may be built in a different institutional context, with different funding norms and greater tolerance for risk.

Second, incumbents may remain competitive in their current markets while still missing the creation of adjacent or entirely new ones. They improve their position in the industries they already understand, but they do not always own the growth curves that emerge from technological discontinuity.

Third, the continent’s capital markets become self-reinforcing. If few large new category leaders emerge, markets continue to favour incumbent-style cash-flow businesses, which in turn strengthens the governance norms that discourage long-duration bets.

Europe then mistakes an outcome of its system for a law of economics. It tells itself that serious industry simply grows at mid-single digits, pays dividends and innovates incrementally, while more volatile growth belongs to a different universe. Yet this is not a natural fact. It is a structural choice embedded in governance, finance and institutional design.

The missing layer: venture creation

The crucial question is therefore not whether large corporations should do research. They should. Nor is it whether startups are inherently superior commercialisers of science. They are not. The question is what sits between research and market creation.

Too often, the answer is very little.

A breakthrough emerges. It is technically promising. It may not fit the current business perfectly. It may need a different business model, different talent, different financing and more tolerance for uncertainty than the core can provide. At this point, many organisations have only two available moves: absorb it into the existing roadmap or let it languish. What they lack is an institutional bridge that can convert the science into a venture.

That bridge requires several things at once. Intellectual-property arrangements that allow new entities to form without endless wrangling. A governance model that can ring-fence risk rather than forcing the core to own all of it directly. Entrepreneurs, whether internal or external, with enough incentive to commit themselves fully. Capital willing to fund a journey rather than a quarter. And strategic sponsorship from the corporation without the suffocating control that kills entrepreneurial agency.

In other words, it requires venture creation as a deliberate capability.

This is what many European ecosystems lack. They know how to fund research. They know how to support collaboration. They know how to help incumbents innovate. They are less skilled at repeatedly turning promising deep technology into companies built for exploration rather than optimisation.

Why this is hard for incumbents to do alone

Even when a corporation recognises the problem, solving it internally is difficult.

The first obstacle is ownership. If the technology is strategically significant, the corporation is reluctant to let it go. Yet if it keeps too tight a grip, the new venture cannot attract founders, capital or agility. The second is control. Corporations want accountability, but startup formation requires room for experimentation, rapid iteration and strategic divergence. The third is incentives. Talented researchers and operators will not take founder-level risk for employee-level upside. The fourth is internal politics. Business units tend to defend budgets, customers and narratives. A new venture that does not fit existing structures can appear as a distraction or threat.

Finally, there is signalling. A listed company that openly incubates long-duration bets outside its core may unsettle investors unless it can explain the logic clearly. Management teams therefore often prefer safer forms of innovation: partnerships, pilots, minority investments, accelerator programmes. These can all be useful. But they are not the same as building a company from a piece of science.

Thus one sees the pattern again. The corporation acknowledges the need for renewal, supports innovation rhetorically and funds serious technical work, yet still struggles to produce new standalone growth businesses. The effort gets trapped between strategic ambition and governance gravity.

Corporate Venture Studios as a structural answer

This is where the idea of venture building within industrial ecosystems becomes important.

A Corporate Venture Studio, properly understood, is not a fashionable startup accessory. It is a structural mechanism for dealing with a problem the core organisation cannot solve on its own. Its role is not to replace corporate R&D or corporate strategy. It is to create a separate but connected pathway through which deep technology, latent market opportunities and industrial capabilities can be turned into ventures with their own incentives, financing logic and room to explore.

That means several things.

It means taking seriously the possibility that some innovations should not be commercialised inside the current business. It means creating repeatable processes for identifying which technologies have venture-scale potential rather than merely product-upgrade value. It means designing ownership models that align the corporation, founders and investors without paralysing the new venture. It means giving entrepreneurs enough autonomy to build a market, not merely execute a corporate pilot. And it means developing a capital strategy that recognises different phases of risk rather than expecting the core P&L to absorb all of it.

For industrial firms, this is uncomfortable but necessary. The alternative is to keep assuming that good research will somehow produce new growth by force of technical merit alone. It will not. Science needs institutions as much as capital. If the institution into which science is born can only turn it into incremental improvement, that is what will happen.

A more realistic ambition for European industry

Some executives may bristle at this diagnosis. Must every industrial firm aspire to create the next ICEYE or IQM? Of course not. Many companies are right to focus on operational excellence, cash generation and leadership in mature sectors. There is nothing dishonourable about being a brilliantly run incumbent.

But the question changes if the aim is not merely to defend current positions but to ensure that Europe captures more of the value from its scientific and engineering base. Then incremental improvement is not enough. The issue is not that incumbents should abandon discipline. It is that the system needs complementary vehicles that can do what the core cannot.

This is particularly important in domains where science, software, hardware and systems integration are converging. Energy, mobility, industrial AI, sensing, defence technology, quantum, robotics, advanced materials and health technology all contain opportunities that may begin as corporate or university research but require venture-style structures to become category-defining companies.

Europe’s industrial champions are well placed to participate in this creation. They possess domain knowledge, customer relationships, regulatory fluency and technical credibility that startups often lack. But to convert those advantages into new-market leadership, they must stop assuming that the core organisation is always the right commercial container.

The conclusion Europe keeps avoiding

So why could an ICEYE or IQM almost never be born inside a European industrial giant?

Not because the science would be impossible there. Quite the opposite. The science could plausibly be born there. The reason is that the corporation would tend to ask the wrong commercial questions at the wrong stage. How does this fit the current portfolio? When does it affect earnings? What is the payback period? How will analysts model it? What does it do to our capital discipline? Can we explain it inside the current strategic story?

Those are sensible questions for a listed industrial company. They are often fatal questions for a new market.

A startup asks different ones. How large could this market become? What must be true for this technology to define a category? Who are the right founders? What kind of capital can sustain the search? What business model does this science imply? Such questions are no guarantee of success. But they are at least aimed at the possibility of creating something new rather than improving something old.

That is the central distinction.

Europe’s challenge, then, is not lack of research, lack of talent or lack of ambition. It is institutional mismatch. The organisations best at producing and refining deep technology are often not the organisations best suited to commercialising it as a new market. Until Europe accepts that point, it will continue to mistake strong R&D inputs for adequate growth mechanisms.

If it wants more companies like ICEYE or IQM, it must build the bridge it currently lacks: from deep research to venture creation to market building. That means treating venture formation not as a peripheral startup exercise but as a core instrument of industrial renewal.

The future will not be won only by those who invent. It will also be won by those who decide, at the moment of invention, what kind of institution gets to carry the idea into the market. On that question, Europe’s large corporations remain full of technical promise, but structurally ill-suited to the task.